Among patients with non–muscle-invasive bladder cancer, neoadjuvant mitomycin demonstrated favorable safety. Among patients with non-muscle-invasive bladder cancer (NMIBC), neoadjuvant treatment with ...

In December 2022, the company reported findings from the Phase IIb OPTIMA II trial of UGN-102 (mitomycin) to treat LG-IR-NMIBC. "UroGen begins subject dosing in Phase III bladder cancer drug trial ...

Two recent analyses provide new insight into the clinical efficacy of BCG versus chemotherapy with mitomycin C in intermediate-risk and high-risk bladder cancer. BCG immunotherapy showed a ...

UroGen Pharma reports strong long-term data for Jelmyto and UGN-102 in cancer studies and shares promising early results for UGN-301 in bladder cancer.

UGN-102 is UroGen’s sustained-release formulation of mitomycin being developed for the treatment of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).